Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Change in Acquisitions & Divestments: 2019-2025

Historic Change in Acquisitions & Divestments for KalVista Pharmaceuticals (KALV) over the last 3 years, with Apr 2025 value amounting to $20.2 million.

  • KalVista Pharmaceuticals' Change in Acquisitions & Divestments rose 30.56% to $20.2 million in Q2 2025 from the same period last year, while for Apr 2025 it was $122.8 million, marking a year-over-year increase of 17.00%. This contributed to the annual value of $122.5 million for FY2025, which is 16.74% up from last year.
  • According to the latest figures from Q2 2025, KalVista Pharmaceuticals' Change in Acquisitions & Divestments is $20.2 million, which was down 58.65% from $48.9 million recorded in Q4 2024.
  • KalVista Pharmaceuticals' Change in Acquisitions & Divestments' 5-year high stood at $48.9 million during Q4 2024, with a 5-year trough of $11.6 million in Q1 2024.
  • Over the past 3 years, KalVista Pharmaceuticals' median Change in Acquisitions & Divestments value was $32.5 million (recorded in 2023), while the average stood at $30.3 million.
  • Over the last 5 years, KalVista Pharmaceuticals' Change in Acquisitions & Divestments had its largest YoY gain of 50.24% in 2024, and its largest YoY loss of 15.77% in 2024.
  • Quarterly analysis of 3 years shows KalVista Pharmaceuticals' Change in Acquisitions & Divestments stood at $32.5 million in 2023, then soared by 50.24% to $48.9 million in 2024, then skyrocketed by 30.56% to $20.2 million in 2025.
  • Its last three reported values are $20.2 million in Q2 2025, $48.9 million for Q4 2024, and $38.2 million during Q3 2024.